Agilon Health Inc (NYSE:AGL)’s traded shares stood at 3.49 million during the last session, with the company’s beta value hitting 0.67. At the close of trading, the stock’s price was $3.28, to imply a decrease of -6.29% or -$0.22 in intraday trading. The AGL share’s 52-week high remains $7.73, putting it -135.67% down since that peak but still an impressive 54.27% since price per share fell to its 52-week low of $1.50. The company has a valuation of $1.35B, with an average of 4.76 million shares in intraday trading volume over the past 10 days and average of 4.59 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Agilon Health Inc (AGL), translating to a mean rating of 2.86. Of 10 analyst(s) looking at the stock, 0 analyst(s) give AGL a Sell rating. 0 of those analysts rate the stock as Overweight while 3 advise Hold as 7 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.13.
Agilon Health Inc (NYSE:AGL) trade information
After registering a -6.29% downside in the last session, Agilon Health Inc (AGL) has traded red over the past five days. The 5-day price performance for the stock is -8.64%, and 59.22% over 30 days. With these gigs, the year-to-date price performance is 72.63%. Short interest in Agilon Health Inc (NYSE:AGL) saw shorts transact 25.25 million shares and set a 6.65 days time to cover.
The extremes give us $2.5 and $4 for target low and target high price respectively. As such, AGL has been trading -21.95% off suggested target high and 23.78% from its likely low.
Agilon Health Inc (AGL) estimates and forecasts
Looking at statistics comparing Agilon Health Inc share performance against respective industry, we note that the company has underperformed competitors. Agilon Health Inc (AGL) shares are -47.27% down over the last 6 months, with its year-to-date growth rate lower than industry average at -34.78% against 5.30%. The rating firms project that company’s revenue will grow 40.30% compared to the previous financial year.
Revenue forecast for the current quarter as set by 19 analysts is 1.52B. Meanwhile, for the current quarter, a total of 13 analyst(s) estimate revenue growth to 1.7B.Earnings reports from the last fiscal year show that sales brought in 1.06B and 1.6B respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 43.84% before jumping 5.87% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 7.65% for the past 5-year period. While 2025 is set for a -15.75% return in earnings, projections for the next 5 years are at 24.06% annually.
AGL Dividends
Agilon Health Inc has its next earnings report out in March. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Agilon Health Inc (NYSE:AGL)’s Major holders
Agilon Health Inc insiders hold 1.81% of total outstanding shares, with institutional holders owning 105.02% of the shares at 106.96% float percentage. In total, 105.02% institutions holds shares in the company, led by CLAYTON, DUBILIER & RICE, LLC. As of 2024-06-30, the company held over 100.0 million shares (or 24.3149% of shares), all amounting to roughly $654.0 million.
The next major institution holding the largest number of shares is FMR LLC with 56.93 million shares, or about 13.8418% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $372.3 million.
